



**HAL**  
open science

# A Novel Human Extravascular Monocyte Subset with Antiviral Functions Is Crucial for Resolving Lung Tissue Infection

Devin Kenney, Aoife O'connell, Anna Tseng, Jacquelyn Turcinovic, Maegan Sheehan, Adam Nitido, Paige Montanaro, Hans Gertje, Maria Ericsson, John Connor, et al.

► **To cite this version:**

Devin Kenney, Aoife O'connell, Anna Tseng, Jacquelyn Turcinovic, Maegan Sheehan, et al.. A Novel Human Extravascular Monocyte Subset with Antiviral Functions Is Crucial for Resolving Lung Tissue Infection. bioRxiv : the preprint server for biology, 2024, 10.1101/2024.03.08.583965 . hal-04751123

**HAL Id: hal-04751123**

**<https://hal.science/hal-04751123v1>**

Submitted on 4 Nov 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

1 **Title: A Novel Human Extravascular Monocyte Subset with Antiviral Functions Is Crucial**  
2 **for Resolving Lung Tissue Infection**

3

4 **Short Title: Extravascular Monocytes Resolve Lung Infection**

5

6 **One sentence summary:** We identified a novel human subset of lung extravascular monocytes  
7 with antiviral functions that play a critical role in resolving SARS-CoV-2 infection from human lung  
8 tissues in an immunologically naïve context.

9

10 Devin Kenney<sup>1,2</sup>, Aoife K. O'Connell<sup>1,2,4</sup>, Anna E. Tseng<sup>1,2,4</sup>, Jacquelyn Turcinovic<sup>1,2,3</sup>, Maegan L.  
11 Sheehan<sup>7,12</sup>, Adam D. Nitido<sup>7,12</sup>, Paige Montanaro<sup>2,4</sup>, Hans P. Gertje<sup>2,4</sup>, Maria Ericsson<sup>6</sup>, John H.  
12 Connor<sup>1,2</sup>, Vladimir Vrbancac<sup>7</sup>, Nicholas A. Crossland<sup>1,2,4</sup>, Christelle Harly<sup>8,9,12\*</sup>, Alejandro B.  
13 Balazs<sup>7,12\*</sup>, and Florian Douam<sup>1,2,12,13\*</sup>

14

15 <sup>1</sup>Department of Virology, Immunology, and Microbiology, Boston University Chobanian &  
16 Avedisian School of Medicine, Boston, MA, USA.

17 <sup>2</sup>National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.

18 <sup>3</sup>Bioinformatics Program, Boston University, Boston, MA, USA.

19 <sup>4</sup>Department of Pathology and Laboratory Medicine, Boston University Chobanian & Avedisian  
20 School of Medicine, Boston, MA, USA.

21 <sup>6</sup>Electron Microscopy Core Facility, Harvard Medical School, Boston, MA, USA.

22 <sup>7</sup>Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.

23 <sup>8</sup>Université de Nantes, INSERM, CNRS, CRCINA, Nantes, France

24 <sup>9</sup>LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France.

25 <sup>12</sup>These authors contributed equally to the work.

26 <sup>13</sup>Lead contact

27 \*Correspondence:

28 Florian Douam, National Emerging Infectious Diseases Laboratories, 620 Albany Street Boston  
29 MA 02118 USA, +1-617-358-9174, [fdouam@bu.edu](mailto:fdouam@bu.edu).

30 Alejandro B. Balazs, Ragon Institute of MGH Harvard and MIT, 400 Technology Square  
31 Cambridge MA 02139 USA, +1-857-268-7197, [abalazs@mgh.harvard.edu](mailto:abalazs@mgh.harvard.edu).

32 Christelle Harly, CRCINA - Institut de Recherche en Santé de Nantes Université, 8 quai  
33 Moncousu 44 007 Nantes France, +33-2 28 08 02 08, [christelle.harly@inserm.fr](mailto:christelle.harly@inserm.fr).

34

35 The authors have declared that no conflict of interest exists.

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53 **ABSTRACT**

54 The recurring emergence of novel respiratory viruses has highlighted our poor understanding of  
55 the human immune mechanisms governing the resolution of lung infection in an immunologically  
56 naïve context. Using SARS-CoV-2 as a prototypical emerging respiratory virus, we leveraged  
57 mice co-engrafted with a genetically matched fetal lung xenograft (fLX) and a human immune  
58 system (BLT-L mice) to investigate such mechanisms. While BLT-L mice effectively resolve  
59 SARS-CoV-2 infection following acute viral replication in fLX, viral clearance is robustly abrogated  
60 through systemic depletion of CD4+, but not CD3+ or CD8+ cells, resulting in persistent infection.  
61 Leveraging single-cell transcriptomics to uncover the CD4-expressing subsets driving infection  
62 resolution, we identified a novel subset of lung extravascular inflammatory monocytes (ExiMO)  
63 with antiviral functions. ExiMO are the dominant CD163-expressing myeloid population emerging  
64 in fLX upon acute infection and derive from recruited circulating CD4+ monocytes. They are highly  
65 enriched in viral RNA and elicit a robust antiviral response before vanishing from tissues when  
66 infection resolves. Notably, systemic CD4+ cell depletion results in impaired recruitment of  
67 CD163+ cells into fLX and leads to a state of immune tolerance and chronic infection defined by  
68 the absence of ExiMO antiviral responses. Together, our study uncovers ExiMO as major  
69 sentinels driving SARS-CoV-2 infection resolution in human lung tissues without pre-existing  
70 immunity. This work expands our understanding of lung extravascular monocytes and unravels  
71 novel facets of the cellular determinants governing our vulnerability to viral respiratory pathogens.

72

73

74

75

76

77

78

## 79 INTRODUCTION

80 Human emerging respiratory viruses (hERVs), including MERS-CoV, new influenza A  
81 strains, and more recently, SARS-CoV-2, the etiologic agent of COVID-19, have reignited the  
82 need to understand immunological mechanisms that can protect us against these pathogens  
83 when no pre-existing and/or cross-reactivity immunity exists. While these non-experienced  
84 immune mechanisms harbor a pivotal role in our inherent resistance against antigenically novel  
85 hERVs and their disruptive impact on public health, the scarcity of experimental systems that  
86 recapitulate lung-resident human immune responses has made their investigation challenging.

87 Human studies are associated with logistical and experimental challenges, such as the  
88 need to capture early pulmonary immune responses in infected individuals and/or in the validation  
89 of purely correlative findings. While these challenges can be overcome through experimental  
90 human infection studies, longitudinal lung-resident immune responses in infected volunteers  
91 remain hardly accessible. Notably, a recent human challenge study uncovered novel  
92 immunological signatures of protection from SARS-CoV-2 in humans (1). However, sample  
93 analysis was limited to peripheral blood and nasopharyngeal swabs, concealing major tissue-  
94 resident immunological processes associated with protection, such as extravasation of recruited  
95 immune lineages and their differentiation process to combat and resolve infection.

96 In contrast, large and small animal models have been developed to support infection with  
97 hERVs. However, the high cost and limited reagent availability associated with non-human  
98 primate models and the large divergence between rodent and human immune systems  
99 underscore the need for additional models capable of recapitulating human protective immune  
100 responses to hERVs in an immunologically non-experienced context.

101 Mice co-engrafted with human fetal lung xenograft (fLX) and a human immune system  
102 (HIS) have been reported to support infection by multiple hERVs, including human  
103 cytomegalovirus (HCMV), Middle East respiratory syndrome coronavirus (MERS-CoV) and  
104 SARS-CoV-2 (2-4), and mount lung-resident human immune responses against these pathogens.

105 Recently, our group reported that mice engrafted with fLX are highly susceptible to SARS-CoV-2  
106 infection and lung tissue damage and support persistent viral infection. However, co-engraftment  
107 of these animals with fLX and a HIS in a xenorecipient strain supporting enhanced myelopoiesis  
108 (i.e., HNFL mouse model) prevented any detectable viral replication in fLX, resulting in complete  
109 lung tissue protection from histopathology (3). Our findings unraveled a human macrophage  
110 antiviral signature as a correlate of non-experienced immunity against SARS-CoV-2 infection.  
111 However, the non-experienced immune mechanisms governing the resolution of SARS-CoV-2  
112 infection in the context of extensive viral replication in lung tissues, which more likely describes  
113 mild cases of COVID-19, have remained elusive. This study, which uses SARS-CoV-2 as a  
114 prototypical hERV, aims to unravel some of these mechanisms.

115 Unlike the HNFL mouse model, immunodeficient mice co-engrafted with fLX and a  
116 genetically matched human immune system, fetal liver, and thymus (BLT-L mice) support acute  
117 SARS-CoV-2 infection, consistent with previous reports (2, 4). However, the infection quickly  
118 resolves following a viral replication peak at 2 days post-inoculation (dpi), making this model  
119 suitable for examining mechanisms of non-experienced antiviral immunity in the context of HERV  
120 infection of lung tissues. Notably, systemic depletion of CD4<sup>+</sup> cells, but not CD3<sup>+</sup> T-cells or CD8<sup>+</sup>  
121 cells, robustly abrogates infection resolution and results in persistent viral replication in fLX of  
122 BLT-L mice. Using single-cell transcriptomic and multiplexed immunohistochemistry (mIHC)  
123 approaches, we uncovered a novel subset of lung extravascular inflammatory monocytes  
124 (ExiMO). ExiMO are directly related to intravascular CD4<sup>+</sup> patrolling monocytes recruited into fLX  
125 during acute infection, and are the dominant CD163-expressing myeloid subset to emerge in fLX  
126 upon acute infection. They are highly enriched in viral RNA and elicit a uniquely robust antiviral  
127 response. In accordance with our depletion findings, CD4<sup>+</sup> cell depletion reduces CD163<sup>+</sup>  
128 recruitment into fLX and promotes a state of immune tolerance characterized by the absence of  
129 major antiviral cytokines expressed by ExiMO. CD4<sup>+</sup> cell depletion also induces systemic and  
130 lung signatures of chronic infection, underlining how ExiMO are critical to avert long-lasting viral

131 persistence. Collectively, our work sheds light on a novel cellular mediator driving naïve immunity  
132 against SARS-CoV-2 in human lung tissues. To our knowledge, our study is the first to uncover  
133 lung extravascular monocytes with antiviral functions and contributes to enhancing our  
134 understanding of the cellular determinants defining human susceptibility to hERVs.

135

## 136 RESULTS

### 137 BLT-L mice effectively clear SARS-CoV-2 infection following acute viral replication

138 Previous work from our laboratory (3) and others (2, 4, 5) have shown that  
139 immunodeficient mice can successfully be engrafted with human fetal lung xenograft (fLX) alone  
140 or in combination with a human immune system (HIS). In this study, we leveraged a previously  
141 reported mouse model co-engrafted with fetal liver and thymus as well as with human  
142 hematopoietic stem cells (HSC) and fLX (BLT-L mice) (5). Fetal liver and thymus were engrafted  
143 under the renal capsule of adult NOD.Cg-*Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup>*/SzJ (NSG) mice (12-16 weeks old)  
144 prior to intravenous HSC injection. A piece of fetal lung tissue was subcutaneously engrafted on  
145 the flank of each animal, as described previously (5). To determine the susceptibility of BLT-L  
146 mice to SARS-CoV-2 infection and their ability to effectively clear infection, BLT-L mice were  
147 inoculated with SARS-CoV-2 (2019-nCoV/USA\_WA1/2020) via intra-graft injection. We used a  
148 viral dose ( $10^6$  PFU) that we previously established to drive robust and persistent infection in fLX  
149 of immunodeficient mice not engrafted with an HIS (3).

150 Throughout the course of infection, mice did not display any weight loss (**Fig. 1A**) or  
151 clinical signs of disease such as lethargy or lack of responsiveness (data not shown). To assess  
152 lung histopathology and viral titers longitudinally, fLX were collected at 2, 6, and 12 dpi.  
153 Immunohistochemistry (IHC) for SARS-CoV-2 Spike (S) protein revealed infection of alveolar  
154 epithelium in fLX at 2 dpi, while the majority of viral antigen was cleared by 6 dpi and became  
155 undetectable by 12 dpi (**Fig.1B<sup>a-d</sup>**). SARS-CoV-2 S was primarily detected in the cytoplasm of  
156 alveolar epithelium morphologically consistent with type II pneumocytes (AT2 cells) and

157 macrophages within alveolar spaces admixed with necrotic cellular debris and bronchiole  
158 epithelium, consistent with the primary cell targets of SARS-CoV-2 (**Fig. 1B<sup>b</sup>**). These findings were  
159 independently confirmed through IHC for SARS-CoV-2 nucleoprotein N (**Fig. S1A-D**).  
160 Transmission electron microscopy (TEM) imaging of fLX at 2 dpi substantiated evidence of  
161 productive fLX infection, as indicated by the presence of viral particles in the cytosol of epithelial  
162 cells and budding/invagination of virions (**Fig. S1E-G**). Viral titer quantification in fLX also  
163 supported evidence of acute infection at 2 dpi prior to effective resolution (**Fig. 1C**). A significant  
164 amount of infectious viral particles could be recovered from fLX at 2 dpi ( $3.20 \pm 2.52 \log$ [PFU/mg  
165 of tissue]), but not at 6 dpi ( $0.281 \pm 0.688 \log$ [PFU/mg of tissue]) and 12 dpi ( $0.111 \pm 0.293$   
166  $\log$ [PFU/mg of tissue]) (**Fig. 1C**).

167 Next, we examined histopathological phenotypes associated with active and resolved  
168 infection. Interpretation of hematoxylin and eosin (H&E) staining illustrated denuding of  
169 pneumocytes, neutrophil infiltration, edema, hemorrhage, thrombosis, and pneumocyte necrosis,  
170 which correlated with sites of infection at 2 dpi (**Fig. 1B<sup>e,f</sup>** and **Fig. S1H-J**). No major disease  
171 phenotypes were observed at 6 and 12 dpi compared to naïve fLX, underscoring that fLX can  
172 mount repair mechanisms upon resolution of infection (**Fig. 1B<sup>g,h</sup>**). A previously described semi-  
173 quantitative histopathological scoring system (3) provided statistical confirmation for a significant  
174 increase in lung pathology at 2 dpi, which was no longer apparent at 6 dpi (**Fig. 1D**) or 12 dpi. Of  
175 note, minor lung pathology was observed at baseline (naïve), likely reflecting limited graft vs. host  
176 disease. Together, BLT-L fLX recapitulates important hallmarks of acute SARS-CoV-2 infection,  
177 including viral replication and histopathological manifestations of disease, prior to effective viral  
178 clearance and lung tissue repair.

179

180 **Humoral responses do not drive SARS-CoV-2 clearance in BLT-L mice despite evidence of**  
181 **Spike selective pressure.**



182 We first asked whether SARS-CoV-2 infection resolution was driven by human  
183 neutralizing humoral responses. No neutralization against infectious SARS-CoV-2 was detected  
184 from the serum of BLT-L mice collected at 2 or 12 dpi (**Fig. S1K,L**). This is consistent with the  
185 rapid clearance of infectious viral particles by 6 dpi, and the known caveat that humanized mice  
186 mount limited humoral responses (6). However, viral genome sequencing from acutely infected  
187 fLX showed that 75% of 2 dpi-associated viral sequences exhibited the selection of two stable  
188 mutations not observed in our inoculum and located in the Spike N-terminal domain (NTD): an  
189 insertion (216KLRS) and a non-synonymous mutation (R245H) (**Fig. S1M,N Table S1**).  
190 Interestingly, these two mutations were found together in 100% of the viral sequences, suggesting  
191 potential co-evolution (**Fig. S1O**). They have also been reported as positively selected in the  
192 context of sub-optimal neutralizing antibody concentration (216KLRS) (7) or in the context of  
193 cross-species adaptation (216KLRS and R245H) (8). Despite the lack of humoral responses,  
194 these findings underscore how BLT-L mice can recapitulate host-pathogen interactions that drive  
195 SARS-CoV-2 evolution and host adaptation.

196

### 197 **Systemic depletion of CD4<sup>+</sup> cells abrogates viral clearance in fLX.**

198 The addition of a human thymus in the BLT-L model generates a more functional T  
199 lymphocyte compartment. Therefore, we wished to examine the contribution of T cells in SARS-  
200 CoV-2 infection resolution. We performed systemic depletion of CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> cells  
201 through the administration of OKT3, OKT4, or OKT8 depleting antibodies, respectively, via  
202 intraperitoneal injection both prior to and after infection (**Fig. 2A**). Effective systemic depletion  
203 was confirmed in the blood by flow cytometry (**Fig. S2A**). All animals were euthanized at 12 dpi  
204 to assess for the persistence of SARS-CoV-2 infection in fLX. While depletion of CD3<sup>+</sup>, CD4<sup>+</sup>,  
205 and CD8<sup>+</sup> cells induced persistent infection in some or most of the animals, only CD4<sup>+</sup> cell  
206 depletion (mean Log PFU/mg tissue = 2.37) resulted in a statistically significant defect in infection  
207 resolution compared to all other experimental conditions (isotype, OKT3, and OKT8-treated mice)

208 **(Fig. 2B)**. The rate of productively infected fLX was also higher in CD4+ cell-depleted animals,  
209 with 72% of fLX (8/11) showing infection at 12 dpi compared to 50% (4/8) and 33% (2/6) in CD3-  
210 and CD8-depleted mice, respectively **(Fig. 2B)**. Additionally, when examining the average viral  
211 titer (Log PFU/mg of tissue) of persistently infected fLX, the ones from CD4+ cell-depleted animals  
212 were significantly higher compared to CD3+ cell- depleted fLX **(Fig. S2B)**, furthering that CD4+  
213 cells have a more consequential impact on driving infection resolution than CD3+ cells. Anti-  
214 SARS-CoV-2 N IHC confirmed these findings and superior defect of CD4+ cell-depleted animals  
215 to resolve infection **(Fig. 2C)**. Using multiplex fluorescent IHC (mIHC), we also validated the  
216 reduction in CD3+, CD4+ and CD3+ CD4- cells in fLX from CD3-, CD4- and CD8-depleted  
217 animals respectively, compared to isotype-treated animals **(Fig.2D)**.

218 Persistent infection in CD4+ cell-depleted animals was also associated with significant  
219 downregulation of MHC class I **(Fig. 2E)**, a phenomenon we similarly observed in acutely infected  
220 fLX (2 dpi) **(Fig. 2E)** and that has been previously reported in cells with active SARS-CoV-2  
221 replication (9, 10). This further emphasizes that depletion of CD4+ cells is associated with  
222 defective viral clearance mechanisms. These findings suggest that circulating CD4-expressing  
223 cells, and to a lesser extent CD3+ T-cells, mediate SARS-CoV-2 infection resolution in BLT-L  
224 mice.

225

## 226 **Human responses to SARS-CoV-2 mobilize specific hematopoietic subsets.**

227 To define the identity of the CD4+, and to a lesser extent, CD3+ subset(s) mediating  
228 infection resolution, we performed single-cell RNA sequencing (scRNA-seq) on fLX from naïve  
229 BLT-L mice and at 2 and 12 dpi. While most cells detected in fLX by scRNA-seq were human, a  
230 minor population of mouse cells were detected, which were excluded from downstream analysis  
231 **(Fig. S3A-C)**. Analysis of the human compartment revealed diverse immune subsets (T  
232 cells/innate lymphoid cells (ILC), B cells, myeloid cells and mast cells) and non-immune cell types  
233 (ciliated and non-ciliated epithelial, endothelial, mesenchymal cells and chondrocytes) in both

234 naïve and infected fLX (**Fig. 3A-C and Fig. S3D,E**). It is important to note that because our tissue  
235 digestion process and scRNAseq (in contrast to single nucleus RNAseq) both favor hematopoietic  
236 cell characterization compared to non-immune compartments (11, 12), the recovery of non-  
237 hematopoietic cell types is reduced, as evidenced by the limited number of cells in the epithelial  
238 compartment. Regardless, the transcriptomic dynamics within each cell type, including  
239 epithelium, could be examined upon infection.

240 Initial analysis showed that the transcriptomic response of the epithelial compartment  
241 upon infection was consistent with previously reported signatures of patients suffering from  
242 COVID-19 (11-13). Indeed, we noted a relative reduction of the alveolar type 2 (AT2)  
243 compartment at 2 dpi (25.6%) compared to naïve mice (73.1%), which was partially restored at  
244 12 dpi (49.1%) (**Fig. 3D,E**). In contrast, the AT1 compartment increased at 2 dpi (9.89% compared  
245 to 8.00% in naïve fLX), consistently with the ability of AT2 cells to differentiate into AT1 upon lung  
246 damage (14). AT2 cells did not exhibit any robust antiviral responses (**Fig. 3F**) in accordance with  
247 the absence of viral RNA in this compartment (**Fig. 3G**). Given the clear evidence of epithelial  
248 infection in fLX at 2 dpi (**Fig. 1B<sup>b</sup>**), the significant cytopathic damages induced by SARS-CoV-2  
249 in AT2 cells (15), which results in a marked reduction of the AT2 compartment upon infection ((16)  
250 and **Fig. 3E**), likely precluded the isolation of infected AT2 cells following fLX digestion and single-  
251 cell isolation. However, bystander, non-infected AT2 cells displayed previously reported COVID-  
252 19 signatures found in humans, including downregulation of MHC genes (*HLA-C*, *HLA-B*, and  
253 *HLA-DPB1*) and *CCL5* (a cytokine associated with immune recruitment during respiratory  
254 infection) (**Fig. 3F**) (17). To summarize, fLX epithelium recapitulated previously reported features  
255 of COVID-19 in humans, including downregulation of immune genes and antigen presentation,  
256 and activation of tissue repair mechanisms.

257 Following epithelial benchmarking, we examined how the overall human immune system  
258 mobilizes within infected fLX. T-cells and innate lymphoid cells (ILC) have the same transcriptional  
259 programs, express TCR genes, and play similar effector functions (18). Their shared features

260 render them very challenging to distinguish by scRNAseq in small datasets and without TCR  
261 sequencing information (19). We thus considered them together as part of a T-cell/ILC population.  
262 T-cell/ILC frequency dramatically decreased in fLX upon infection (naïve, 66.8%; 2 dpi, 35.3%;  
263 12 dpi, 21.8%), which is consistent with evidence that COVID-19 can induce lymphocyte depletion  
264 (**Fig. 3B,C**). Notably, lymphopenia was not observed in the peripheral blood of BLT-L mice,  
265 suggesting that lymphocyte depletion in fLX was not directly attributed to declining circulating  
266 peripheral lymphocytes (**Fig. S3F**). In contrast, myeloid (naïve, 9.94%; 2 dpi, 25.3%; 12 dpi,  
267 22.2%) and B-cell subsets (naïve, 3.64%; 2 dpi, 5.38%; 12 dpi, 5.31%) relatively expanded upon  
268 infection (**Fig. 3A-C**).

269 One myeloid and one T-cells/ILCs populations showed clear segregation by time point  
270 (population A and B in **Fig. 3B**) and were specific to 2 dpi. Most notably, these two hematopoietic  
271 sub-clusters were also highly enriched in viral RNA compared to other hematopoietic lineages  
272 (population A and B; **Fig. 3G, H**). While mesenchymal subsets also exhibited high levels of viral  
273 reads (**Fig. 3G**), reads were limited and distributed sporadically without significant enrichment  
274 within a given sub-cluster (**Fig. 3H and Fig. S3G**), including a 2 dpi-specific mesenchymal sub-  
275 cluster (Population C; **Fig. 2B**), underscoring a lack of association between viral RNA and  
276 mesenchymal activation upon SARS-CoV-2 challenge. Given their high enrichment in viral RNA  
277 and temporal association with acute viral replication, this initial transcriptomic analysis highlights  
278 the 2 dpi-specific myeloid and T-cells/ILCs populations identified as significant candidates in our  
279 search for the cellular mediators of infection resolution.

280

### 281 **Inflammatory monocytes are major drivers of myeloid antiviral responses upon infection.**

282 Next, we wished to examine more closely the transcriptomic profile of the viral RNA  
283 positive-myeloid and T/ILC populations. Since CD4<sup>+</sup> cell depletion had a statistically significant  
284 impact on infection resolution compared to CD3<sup>+</sup> cell depletion (**Fig. 2B**), and given that human  
285 monocytes, as well as some macrophages and dendritic cells (DC), also express CD4 (20, 21),

286 we first focused our study on the myeloid compartment. Sub-clustering of myeloid lineages  
287 unveiled diverse subpopulations, including alveolar and interstitial macrophages, various  
288 monocytes subsets, and one conventional DC subset (cDC) (**Fig. 4A and Fig. S4A-C**). Notably,  
289 we found the 2 dpi-specific viral RNA-enriched myeloid subset, earlier referred to as population B  
290 (**Fig. 4A-C and Fig. 3B,H**), to bear a signature of inflammatory monocytes (iMO) (**Fig. 4A,D-G**  
291 **and Fig. S4D**). iMO exhibited elevated expression of *VCAN*, *S100A8*, *CD14*, *CD163* and  
292 absence/minimal expression of *CD4*, *MARCO* and *CD206 (MRC1)* (**Fig. 4D-F and Fig. S4D**).

293 Only iMO and alveolar macrophages increased in frequencies upon acute infection,  
294 whereas cDC and interstitial macrophage frequencies decreased (**Fig. 4G**). iMO were the most  
295 abundant lineage at 2 dpi (33.5%; **Fig. 4G**) and were the leading mediators of antiviral responses,  
296 as exemplified by the robust upregulated expression of interferon-stimulated genes (ISGs) and  
297 inflammatory cytokines (*CCL8*, *CXCL10*, *CCL2*, *ISG15*, *DEFB1*, *IL1RN*, *IFIT1*, *ISG20*, *IFIT3*, and  
298 *MX1*), as well as inflammatory markers such as *CD163* (**Fig. 4D,H**). While some ISGs (e.g.,  
299 *ISG15*, *IFIT3*, and *MX1*) were expressed in other myeloid lineages at 2 dpi, their expression was  
300 markedly lower compared to iMO, suggesting a strong association between viral RNA and  
301 potentiated antiviral responses. Notably, upregulation of *CCL8*, *CXCL11* and *DEFB1* transcripts  
302 were the most exclusive to iMO (**Fig. 4H**).

303 As a side note, we also examined whether viral RNA-associated iMOs (CoV-iMOs)  
304 displayed a specific transcriptomic signature compared to iMOs (noCoV-iMOs) with undetectable  
305 viral RNA. Notably, only two genes correlated with the presence of viral RNA in iMOs: *FGL2* and  
306 *C15orf48* (**Fig. 4I**). While *FGL2* was down-regulated in CoV-iMO compared to noCoV-iMOs,  
307 *C15orf48* was upregulated. Soluble FGL2 exerts immunosuppressive functions (notably by  
308 inhibiting the NF- $\kappa$ B pathway) (22). Conversely, the mitochondrial protein C15orf48 is positively  
309 regulated by NF- $\kappa$ B signaling (23) and has previously been implicated in severe COVID-19, acting  
310 as a positive regulator of inflammation (24).

311           These findings underscore CD163+ iMO as major mediators of antiviral responses within  
312 myeloid subsets and suggest that productive or abortive SARS-CoV-2 infection could further  
313 potentiate iMO inflammation through a specific set of genes.

314

### 315 **iMO are extravascular and derive from patrolling CD4+ monocytes**

316           As iMO could contribute to infection resolution in BLT-L mice, we sought to understand  
317 the origin of this transient cell subset using scRNA-seq, and cross-validate our findings using  
318 mIHC approaches. We found that low expression of *CD4* was a defining feature of iMO amongst  
319 monocyte sub-lineages (**Fig. 4E**), suggesting that iMO differentiation may be associated with loss  
320 of *CD4* expression. In parallel to this observation, we noted a large population of *CD4+* *CD163-*  
321 *CD206(MRC1)*-patrolling intravascular monocyte (PIM) at all time points (**Sub-cluster 0; Fig.**  
322 **4A,D-F**), with 2 dpi-specific PIM harboring a transcriptomic signature bridging naïve PIM and 2  
323 dpi-specific iMO. At 12 dpi, PIM was the dominant subset over other monocyte subsets (50.3%;  
324 **Fig. 4G**). These results suggest that the infiltration and activation of PIM in fLX upon infection  
325 gives rise to a transient CD163+ iMO population contributing to infection resolution (**Fig. 4J**).

326           Analysis of myeloid chemotaxis transcriptomic signatures was consistent with increased  
327 monocyte infiltration into fLX upon infection. Productive infection of fLX at 2 dpi resulted in the  
328 emergence of cell subsets expressing high levels of human *CCL2* (**Fig. S4E**), which include our  
329 CD163+ iMO subset and a 2 dpi-specific T-cells/ILCs sub-cluster (population A in **Fig. 3B**).  
330 Activation of alveolar macrophages upon acute infection was also associated with increased  
331 *CCL2* expression by these cells (**Fig. S4E**). Several transcripts involved in myeloid chemotaxis,  
332 such as *CXCR4* and *MCAM* (25, 26), were also upregulated in activated, 2 dpi-specific endothelial  
333 cell sub-cluster (**Fig. S4G-I**), underscoring the potential contribution of the endothelium in myeloid  
334 recruitment.

335           In support of our transcriptomic findings, mIHC analysis revealed that while naïve fLX  
336 displayed high numbers of CD3+ cells and detectable CD163+ interstitial cells (likely

337 macrophages), acute infection at 2 dpi showed an increase in CD4<sup>-</sup> CD163<sup>+</sup> cells both in the  
338 extravascular interstitium and alveolar spaces (**Fig. 4K**). These dynamics mirrored the 2 dpi-  
339 specific expansion of CD4<sup>-</sup> CD163<sup>+</sup> iMO and alveolar macrophages uncovered through scRNA-  
340 seq (**Fig. 4G**). A significant number of CD4<sup>+</sup> CD3<sup>-</sup> CD163<sup>-</sup> cells were also apparent at that time  
341 point by mIHC (**Fig. 4K**), which is consistent with the identification of CD4<sup>+</sup> CD163<sup>-</sup> PIM at 2 dpi  
342 by scRNAseq (**Fig. 4B,D,E**). Reduction of CD3<sup>+</sup> T-cell was also apparent at 2 dpi (**Fig. 4K**) in  
343 accordance with our scRNAseq findings (**Fig. 3C**). At 12 dpi, CD3<sup>-</sup> CD4<sup>+</sup> cells were still noted in  
344 fLX (**Fig. 4K**), reflecting the expansion of CD4<sup>+</sup> PIM observed by scRNAseq (**Fig. 4G**). A  
345 significant number of CD163<sup>+</sup> cells were still observed in fLX at that time point (**Fig. 4K**) but  
346 mainly concentrated in the interstitium, consistent with our scRNA findings that an increase in  
347 CD163<sup>+</sup> interstitial macrophages may concur simultaneously with the reduction in CD163<sup>+</sup> iMO  
348 numbers (**Fig. 4G**).

349 Concomitant to a recent study reporting that PIM give rise to a non-classical, extravascular  
350 monocyte population in the mouse lung that expand upon stimuli (25), our mIHC and scRNA-seq  
351 findings collectively suggest that infiltration of CD4<sup>+</sup> PIM in infected fLX precede PIM  
352 extravasation and differentiation into extravascular iMO. In further support of this extravascular  
353 nature of iMO, the iMO gene expression profile was similar to those of human FCN1-monocytes  
354 recovered from the broncho-alveolar lavage of COVID-19 patients with acute respiratory disease  
355 syndrome (26), overall strengthening the non-classical, extravascular monocyte nature of iMO  
356 and their human relevance in COVID-19. Extravascular iMO are referred to as ExiMO in the rest  
357 of our study.

358

### 359 **CD4<sup>+</sup> cell depletion disrupts CD163<sup>+</sup> cell recruitment into productively infected fLX.**

360 Productive fLX infection at 2 dpi is associated with a significant increase in CD163<sup>+</sup> cells  
361 in fLX (**Fig. 4K**), which is dominantly attributed to ExiMO differentiation as per our scRNA-seq  
362 data (**Fig. 4B,D**). At 12 dpi, the overall amount of CD163<sup>+</sup> cells in fLX remained high (**Fig. 4K**)



363 and was not statistically different from the amount of CD163+ cells observed at 2 dpi (**Fig. 5A,B**),  
364 which is likely the manifestation of the presence of residual ExiMO and of the differentiation of  
365 CD163+ CD206+ interstitial macrophages from infiltrating CD4+ CD14+ CD16- monocytes at 12  
366 dpi (**Fig. 4D,G**) consistently with the literature (27). As our data support a model in which  
367 infiltrating CD4+ PIM differentiate into CD163+ ExiMO and interstitial macrophages upon and  
368 following infection respectively, we examined how CD4+ cell depletion impacts CD163+  
369 recruitment in fLX. Of note, because of the limited accessibility of fetal tissues and of a conscious  
370 choice to limit our use of such tissue as much as possible, we restricted our analysis to a single  
371 time point. We chose to focus our analysis on phenotypes observed at 12 dpi to ensure their  
372 association with persisting infection (in contrast to acute infection).

373       Following CD4+ cell depletion, persistently infected fLX displayed a significantly reduced  
374 number of CD163+ cells in fLX compared to isotype-treated and non-treated mice at 12 dpi (**Fig.**  
375 **5A,B**). Expectedly, a major reduction was observed in the interstitial space (**Fig. 5A**), consistently  
376 with reduced numbers of ExiMO and interstitial macrophages. Limited numbers of alveolar  
377 CD163+ cells were still observed in the fLX of CD4+ cell-depleted mice co-localized with PPAR $\gamma$   
378 (**Fig. 5A**), a marker of lung alveolar macrophages, which are unlikely to be depleted by anti-CD4  
379 antibodies consistently with the known limited accessibility of alveolar macrophages to systemic  
380 antibodies (28). Despite being both similarly infected, fLX of acutely infected mice (2 dpi) also  
381 displayed significantly higher numbers of CD163+ cells than persistently infected fLX (12 dpi)  
382 (**Fig. 5A,B**). These findings support evidence that CD4+ cell depletion prevents monocyte  
383 infiltration into fLX during and following infection, and consequentially any differentiation into  
384 CD163+ cells. Notably, systemic levels of human CCL2 and CCL3, major monocyte attractants,  
385 were elevated in CD4+ cell-depleted mice and comparable to those of acutely infected mice (**Fig.**  
386 **5C**), underlining how defective CD163+ recruitment stems from a lack of circulating CD4+ cells  
387 rather than reduced chemotaxis. Together, our findings therefore suggest that CD4+ cell depletion  
388 abrogates the recruitment of ExiMO in infected fLX.



389

390 **Depletion of CD4+ cells in BLT-L mice promotes an immune tolerance state defined by the**  
391 **lack of CXCL10 production**

392 To further support a link between CD4+ cell depletion, persistent infection and lack of  
393 ExiMO differentiation, we compared antiviral responses during acute and persistent infection.  
394 Among 32 cytokines and chemokines analyzed in the peripheral blood, CXCL10 was the only  
395 cytokine displaying significantly increased serum levels in acutely infected mice (2 dpi) prior to  
396 returning to undetectable levels upon infection resolution (12 dpi) (**Fig 5D**). However,  
397 interestingly, levels of circulating human CXCL10 in persistently infected CD4+ cell-depleted mice  
398 were not statistically different than those of mice that resolved infection (12 dpi) (**Fig 5D**),  
399 suggesting that CD4+ cell depletion promotes a state of immune tolerance that favors viral  
400 persistence. These findings also underscore systemic CXCL10 as a biomarker of viral clearance.

401 Several human subsets within fLX express *CXCL10* upon acute infection, including  
402 myeloid, mesenchymal and endothelial subsets (**Fig. S5A,B**). Among mesenchymal subsets,  
403 activated fibroblasts were enriched in *CXCL10* transcripts (**Fig. S5C-E**) unlike activated  
404 endothelial cells (**Fig. S4I**). However, the myeloid compartment was the major source of *CXCL10*  
405 among all human clusters at 2 dpi (**Fig. S5A,B**) and this phenotype was dominantly driven by  
406 ExiMO (**Fig. 4H, S5B**). These observations underscore ExiMO as the dominant producer of  
407 CXCL10 upon acute infection and as a significant source of this potential biomarker of infection  
408 resolution.

409 Taken together, our results suggest that CD4+ cell depletion prevents the induction of  
410 antiviral cytokines (i.e., CXCL10) dominantly expressed by ExiMO, resulting in a state of immune  
411 tolerance that likely favor viral persistence. Combined with evidence that such a depletion  
412 abrogates the recruitment of CD163+ cells into fLX upon infection and that ExiMO are the  
413 dominant CD163-expressing cell population differentiating upon acute infection, these findings  
414 collectively underscore ExiMO as critical mediators of infection resolution.

415

416 **Persistent infection is associated with systemic and local signatures of chronic infection.**

417 To probe whether CD4<sup>+</sup> cell depletion and the lack of CD163<sup>+</sup> cell recruitment drive long-  
418 lasting viral persistence instead of simply delaying infection resolution, we investigated whether  
419 immune tolerance in CD4<sup>+</sup> cell-depleted mice is associated with signatures of chronic infection.  
420 Notably, persistently-infected mice antiviral responses were distinguishable from acutely infected  
421 (2 dpi) and isotype-treated (12 dpi) mice by elevated levels of CCL19 in serum (**Fig. 5E**). CCL19  
422 is a pro-inflammatory cytokine that has been linked with persistent viral replication and  
423 inflammation such as in the context of HIV-1 infection (29), underlining that persistent SARS-CoV-  
424 2 infection in BLT-L mice recapitulate key immunological features of chronic viral infection.

425 We have previously reported that fLX exhibit significant histopathological manifestations  
426 of disease upon SARS-CoV-2 infection in the absence of an engrafted human immune system  
427 (3), highlighting that tissue damage in fLX is virally induced. However, persistent infection did not  
428 result in any significant histopathological manifestations of disease in fLX, which strongly  
429 contrasts with acutely infected fLX (**Fig. 1D, Fig. 5F**). As minimal tissue damage is a hallmark of  
430 chronic viral infection (30), these findings further support evidence that CD4<sup>+</sup> cell depletion  
431 promotes tissue remodeling processes underlying chronic infection and lasting viral persistence.

432

433 **Macrophage-like T-cells are enriched in viral RNA and mount robust antiviral signatures.**

434 Lastly, we aimed to complete our study by characterizing the 2 dpi-specific T-cell/ILC sub-  
435 cluster emerging upon acute infection (population A in **Fig. 3B**), as CD3<sup>+</sup> cell depletion had a  
436 moderate, albeit non-significant, impact on infection resolution (**Fig. 2B**). T-cell/ILC responses  
437 were limited to this specific subpopulation (**Fig. 6A,B**), which clustered very distinctively from  
438 other CD3<sup>+</sup> T-cell lineages, including canonical CD4<sup>+</sup> and CD8<sup>+</sup> T-cells, and was highly enriched  
439 in viral RNA (Sub-cluster 6; **Fig. 6A-C**). Cells included in this subpopulation displayed low levels  
440 of CD4 and CD8 transcripts and elevated levels of mitochondrial transcripts (**Fig. 6E; Fig. S6A,B**).

441 Most notably, this T-cell/ILC subset was uniquely defined by the expression of several transcripts  
442 known to be enriched in macrophages (*MARCO*, *TIMP1*, *LYZ*), fibroblasts (*MGP*, *CALD1*,  
443 *COL1A*), or both (*A2M*, *IFITM3*) but not in T-cells (**Fig. 6E and Fig. S6D**). Cells included in this  
444 subset also exhibited evidence of cytotoxic function through the expression of *GZMA*, *GZMB*, and  
445 *GNLY* transcripts, albeit expression was also detected in CD8<sup>+</sup> T-cells and activated tissue-  
446 resident memory T-cells (TRM) (Sub-clusters 1,3,4, **Fig. 3E and Fig. S3D**). Given the proximity  
447 of this sub-cluster with myeloid lineages (**Fig. 3A,B**) and evidence of expression of macrophage-  
448 enriched transcripts, we referred to this unique sub-cluster as Macrophage-like T-cells (MTC).  
449 MTC also exhibited upregulation of key gene pathways related to COVID-19, SARS-CoV-2 cell-  
450 intrinsic immune responses, cellular cytotoxicity (e.g., degranulation) and cell death, consistently  
451 with a role for this subset to serve as a robust primary responder to viral infection. (**Fig. 6D**).  
452 Collectively, these findings suggest a potential link between our CD3<sup>+</sup> cell-depletion findings and  
453 the innate antiviral responses of CD3<sup>+</sup> MTC.

454

## 455 **DISCUSSION**

456 As our appreciation of the immunological differences between mice and humans continues  
457 to grow, humanized mouse models are increasingly standing out as robust platforms to  
458 understand how viral pathogens interact with human tissues and the human immune system.  
459 These models are especially valuable when investigating tissue and mucosal immunity since such  
460 investigations remain impractical in human patients.

461 The SARS-CoV-2 pandemic has emphasized the need to increase our understanding of  
462 immune mechanisms that can drive protection against immunologically novel respiratory viruses.  
463 Mice engrafted with human immune systems and human lung tissues have emerged as valuable  
464 tools for such investigations (2-5), bridging the limitations of conventional animal models and the  
465 challenges associated with human studies. We previously reported using the HNFL mouse model  
466 that such models can be leveraged to capture immunological signatures defining effective control

467 of SARS-CoV-2 infection (3). However, the enhanced myeloid reconstitution of the HNFL model  
468 rapidly inhibits viral replication in fLX, precluding our ability to study protective naive  
469 immunological mechanisms at play upon acute and potentially symptomatic infection. This study  
470 aimed to uncover novel facets of these mechanisms using an alternative humanized mouse model  
471 that exhibits robust susceptibility to acute hERV infection and a robust ability to resolve infection  
472 in a hematopoietic-dependent manner.

473 We found that BTL-L mice are able to effectively clear both infectious viral particles and  
474 viral RNA following an early peak of viral replication in fLX. Systemic depletion of CD4+, but not  
475 CD3+ or CD8+ robustly abrogates infection resolution, underlining the contribution of the human  
476 hematopoietic compartment in this process. This is consistent with evidence that immunodeficient  
477 mice only engrafted with fLX are unable to clear infection (3, 31). Leveraging scRNAseq  
478 approaches, we uncovered ExiMO as a transient and novel subset of extravascular monocytes.  
479 ExiMO are directly related to CD4+ PIM and are the dominant CD163-expressing myeloid subset  
480 to emerge in fLX upon acute viral replication. They are also highly enriched in viral RNA and  
481 display unique antiviral and myeloid transcriptomic signatures. Notably, CD4+ cell depletion  
482 abrogates CD163+ infiltration in fLX despite persisting viral replication and promotes a state of  
483 immune tolerance defined by the lack of an antiviral cytokine, CXCL10, defining effective infection  
484 resolution and dominantly expressed by ExiMO. Lastly, we uncovered that CD4+ cell depletion is  
485 also associated with signatures of chronic infection systemically and in fLX.

486 All of our findings unequivocally converge toward a critical role of ExiMO in driving infection  
487 resolution in fLX. These cells belong to the only subset displaying the four following features: 1)  
488 a dominant CD163-expressing population that emerge during acute infection, 2) a major source  
489 of *CXCL10* expression, 3) a high enrichment in viral RNA and 4) the induction of robust antiviral  
490 responses. Our study therefore unravels ExiMO recruitment into lung tissues as a critical  
491 immunological process driving effective infection resolution and prevention of chronic infection.  
492 Notably and to the best of our knowledge, our study represents the first evidence of a lung

493 monocyte extravascular subset with antiviral functions. Extravascular monocytes are known to  
494 originate from circulating patrolling monocytes and have been proposed to serve as immune  
495 sentinels through their position at the interface of the lung capillaries and alveoli(25, 32). However,  
496 although previous research reported that these cells can promote T-cell resident memory  
497 differentiation following viral infection (33), their direct antiviral functions have not been  
498 documented until now.

499

500 Our study collectively illuminates a novel immunological model that may—in part—define  
501 naïve antiviral immunity against SARS-CoV-2 and potentially other hERVs in the human lung  
502 (**See Graphical Abstract**). We propose that upon infection of fLX, initial epithelial infection  
503 triggers the activation of fibroblasts and endothelial cells. While fibroblasts potentiate initial  
504 myeloid inflammatory responses, endothelial activation, and CCL2 production by several  
505 activated subsets (of mesenchymal and myeloid origin) promote PIM infiltration into fLX. Following  
506 extravasation, PIM then subsequently differentiate into ExiMO, which may exert a bimodal  
507 function: they drive tissue-wide antiviral responses protecting the epithelial compartment from  
508 persistent infection, and phagocyte viral particles and components, heightening their antiviral  
509 responses. Infection resolution is associated with a significant reduction of ExiMO in fLX,  
510 subsequent infiltration of PIM and differentiation into CD206+ interstitial macrophages which  
511 promote tissue repair. By preventing PIM infiltration into fLX and subsequent ExiMO differentiation  
512 and antiviral responses, CD4+ cell depletion promotes a state of immune tolerance driving long-  
513 lasting viral persistence.

514 Through such model, our findings significantly enhance a recent human study reporting  
515 that protection from SARS-CoV-2 infection is associated with a rapid monocyte response in the  
516 nasal cavity and a decreased number of circulating monocytes(1). Specifically, our work extends  
517 the findings of this human study beyond the limitations of the human model by exploring tissue-  
518 resident events, unraveling the identity of monocyte populations that extravasate tissues,

519 differentiate and mount tissue-resident immune responses to clear infection. By providing  
520 enhanced resolution on key protective immunological processes and mediators that human  
521 studies alone cannot capture, underscoring how human and humanized mouse studies can  
522 effectively complement themselves for improving our understanding of human antiviral immunity.

523

524         While our study emphasizes the protective role of monocytes in preventing severe COVID-  
525 19, monocytic lineages have also been extensively associated with severe COVID-19 (11-13, 26).  
526 Excessive monocyte infiltration, macrophage inflammation and fibrotic response can lead to  
527 potentially fatal acute respiratory distress syndrome (ARDS) and fibrosis despite promoting  
528 infection resolution. A suspected driver of excessive myeloid inflammation is the ability of SARS-  
529 CoV-2 to trigger abortive infection of both monocytes and macrophages (34-37) through viral RNA  
530 replication and protein production, which results in inflammasome activation (37-39). However,  
531 viral RNA in ExiMO is associated with rapid infection resolution and tissue protection. These  
532 findings suggest that monocytic infection can also be associated with positive clinical outcomes  
533 and that the inflammatory trajectory of infected monocytes may define the course of COVID-19.

534         By 12 dpi and infection resolution, fLX displayed residual ExiMO and were enriched in  
535 CD4<sup>+</sup> PIM and CD163<sup>+</sup> CD206<sup>+</sup> interstitial macrophages. These findings are consistent with  
536 mouse studies reporting that CD206<sup>+</sup> interstitial macrophages are involved in response to  
537 wounding and infection recovery, while CD206<sup>-</sup> interstitial macrophages are primary responders  
538 to infection and more pro-inflammatory (25). However, human patients experiencing severe  
539 COVID-19 and ARDS display an accumulation of pro-fibrotic CD163<sup>+</sup> CD206<sup>+</sup> monocyte-derived  
540 interstitial macrophages (26). These cells have been shown to directly derive from extravasating,  
541 circulating CD14<sup>+</sup> monocytes in another human immune system-engrafted mouse model(27),  
542 suggesting that exacerbated monocyte infiltration and differentiation into CD206<sup>+</sup> interstitial  
543 macrophages are a significant driver of COVID-19 disease as viral infection is being cleared in  
544 lung tissues. In addition to this, other studies have reported that PIM can give rise to lung

545 extravascular monocytes in mice (25). These cells exhibit a dynamic transition state and can  
546 differentiate into CD206<sup>-</sup> interstitial macrophages. However, notably, no CD206<sup>-</sup> macrophages  
547 were observed in infected fLX at any time point. Together, these findings suggest that the absence  
548 of ExiMO differentiation into CD206<sup>-</sup> interstitial macrophages during infection represents a  
549 defining hallmark of protection from severe COVID-19. Limited differentiation would avert  
550 uncontrolled and imbalanced inflammation during infection resolution, preventing severe tissue  
551 damage and subsequent exacerbated monocyte differentiation into pro-fibrotic CD206<sup>+</sup> interstitial  
552 macrophages (**Figure 7**). Together, our study suggests that ExiMO antiviral responses represent  
553 a critical crossroad that can shape the clinical trajectory of SARS-CoV-2 infection.

554

555         Our findings call for numerous follow-up investigations. Understanding the cellular and  
556 molecular actors defining the fate of ExiMO upon exposure to SARS-CoV-2 and how key  
557 regulatory crossroads in this subset may result in differential clinical outcomes is of particular  
558 interest. Compounding immune dysregulations, such as elevated inflammatory baseline and/or  
559 specific myeloid imprinting, may contribute to PIM and/or ExiMO's inability to adequately regulate  
560 their activation in a timely manner upon encountering viral materials or inflammatory clues,  
561 leading to rapid differentiation into macrophages and exacerbated inflammation. Our study also  
562 creates a mandate for probing the ubiquitous nature of ExiMO antiviral responses during other  
563 respiratory viral infections and investigating more comprehensively the antiviral functions of this  
564 novel subset beyond SARS-CoV-2 infection. Investigating the contribution of endothelial  
565 activation in driving effective monocyte infiltration and infection resolution, as well as these cells'  
566 contribution to ExiMO differentiation, is also of particular significance. It remains unclear as to  
567 how endothelial and fibroblasts are activated during infection as neither cell population displayed  
568 signs of viral RNA enrichment. Whether activation of these cells is triggered indirectly by early  
569 epithelial and/or myeloid activation, or via direct exposure to viral components such as the  
570 nucleocapsid protein (40) could be investigated using the BLT-L mouse model.



571

572 In parallel to ExiMO, we also identified MTC, a transient T-cell population highly enriched  
573 in viral RNA and only observed upon acute infection. MTC exhibited expression of key  
574 macrophage-defining genes and elevated cytotoxic activity. While this population presents some  
575 similarity with innate-like T-cells (41), which harbor cytotoxic signatures and whose roles in cancer  
576 have been investigated, MTC appear to be unique given their combination of lymphoid, myeloid  
577 and mesenchymal markers and their short-lived, apoptotic nature suggested by their complete  
578 absence at 12 dpi. MTC also share transcriptomic similarities with  $\gamma\delta$  T-cell subsets previously  
579 described as bearing myeloid and cytotoxic functions (42, 43). However, their expression of  
580 conventional macrophage makers emphasizes their uniqueness. While CD8<sup>+</sup> T-cells and  
581 macrophages isolated from nasopharyngeal swabs have been identified to harbor SARS-CoV-2  
582 RNA in human challenge studies(1), MTC did not meet the canonical transcriptomic signatures of  
583 these subsets, suggesting the existence of tissue-resident events driving specific cellular  
584 differentiation processes upon infection. Additional investigations are required to better  
585 understand the identity, fate and functions of this novel cell subset in lung antiviral immunity.  
586 However, it is tempting to speculate that MTC may uniquely synergize CD8<sup>+</sup> cytotoxic T-cell  
587 functions with viral particle phagocytosis to effectively control infection prior to undergoing rapid  
588 cell death.

589 Despite our findings related to MTC, the contribution of T-cells in SARS-CoV-2 infection  
590 resolution remains elusive in our model. CD3<sup>+</sup> cell depletion resulted in a partial abrogation of  
591 infection resolution, with 50% of animals still capable of clearing infection. In addition, even when  
592 viral infection persisted in CD3<sup>+</sup> cell-depleted animals, viral titers in fLX remained significantly  
593 lower than in the fLX of persistently infected CD4<sup>+</sup> cell-depleted animals (**Fig. S2B**). One possible  
594 interpretation is that T-cell depletion delays but does not abolish infection resolution. CD8<sup>+</sup> cell-  
595 depleted mice may display delayed viral clearance compared to isotype-treated mice (with  
596 resolution occurring between 6 dpi and 12 dpi), and CD3<sup>+</sup> T-cell-depleted mice may be



597 undergoing progressive resolution by 12 dpi until complete clearance by a later time. In contrast,  
598 the viral titer observed in fLX of CD4+ cell-depleted mice show no evidence of ongoing infection  
599 resolution. How CD3+ depletion may impact MTC differentiation, and how T-cells (including MTC)  
600 and ExiMO functions may synergize to rapidly resolve infection without extensive inflammation-  
601 induced tissue damage will need further investigation.

602

603         There are inherent limitations associated with the BLT-L mouse model. First, direct viral  
604 inoculation into fLX potentially bypasses key immune checkpoints in the upper respiratory tract,  
605 which are not recapitulated in our model. Second, the hematopoietic reconstitution and functions  
606 of the BLT-L mouse model remain imperfect, notably through the underrepresentation of specific  
607 hematopoietic subsets, including dendritic cells and granulocytes, and limited B-cell responses –  
608 which may ultimately bias the dynamics of viral clearance. Despite these limitations, BLT-L mice  
609 recapitulated human lung responses to SARS-CoV-2 infection through AT2 loss of programming,  
610 fibroblast and endothelial activation, effective clearance of infection through robust hematopoietic  
611 responses. This mouse model also supported viral adaptation processes with public health  
612 relevance, and recapitulated signatures of persistent viral replication observed in patients  
613 suffering from chronic infection. Our work demonstrates the potential of the BLT-L mouse model  
614 to uncover naïve immune mechanisms and mediators governing the effective resolution of lung  
615 infection by SARS-CoV-2. Our findings open avenues for a comprehensive examination of the  
616 antiviral roles of ExiMO against hERV, which may pave the way toward innovative immunotherapy  
617 strategies against these pathogens.

618

## 619 **AUTHOR CONTRIBUTIONS**

620 D.K., A.B.B. and F.D. conceptualized the overall study. C.H. conceptualized the computational  
621 component of this study and oversaw the analysis of the single-cell RNA sequencing data. D.K.,  
622 A.B.B., N.A.C. and F.D. designed the experiments. D.K., A.K.O., M.S, A.N, H.P.G., M.E., V.V.,

623 A.B.B. and F.D. performed experiments. D.K., A.K.O., A.T., J.T., M.S, A.N, P.M., M.E., J.H.C.,  
624 V.V., N.A.C., C.H., A.B.B. and F.D. analyzed the data. J.T and C.H. carried out computational  
625 analysis. M.E. carried out electron microscopy analysis. A.B.B. and V.V. provided access to key  
626 resources. D.K. and F.D. wrote the manuscript with contributions from all authors.

627

## 628 **ACKNOWLEDGMENTS**

629 This work was supported in part by a start-up fund and Peter Paul Career Development  
630 Professorship from Boston University (to F.D.), grants from the National Institutes of Health (K22  
631 AI144050 to F.D.), Clinical and Translational Science Awards (grant UL1 TR001430) from the  
632 National Center for Advancing Translational Sciences of the National Institutes of Health (to F.D.,  
633 N.A.C. and A.E.), and an Evergrande MassCPR award (to R.B.). A.B.B. was supported by  
634 R01AI174875, R01AI174276, DP2DA040254, as well as CDC subcontract 200-2016-91773-  
635 T.O.2. and a Massachusetts Consortium on Pathogenesis Readiness (MassCPR) grant. We also  
636 thank the Evans Center for Interdisciplinary Biomedical Research at Boston University Chobanian  
637 and Avedisian School of Medicine for their support of the Affinity Research Collaborative on  
638 'Respiratory Viruses: A Focus on COVID19'. This work utilized a Ventana Discovery Ultra and  
639 Akoya Phenolmager HT that were purchased with funding from National Institutes of Health SIG  
640 grants (S10 OD026983 & S10OD030269). We thank Ronald B. Corley, NEIDL director at the time  
641 of this study and MassCPR award recipient, for his constant encouragement and support for this  
642 study. We thank the Boston University Animal Science Center, the Ragon Institute Human  
643 Immune System Mouse core, the single cell sequencing core and microarray and sequencing  
644 core, and the flow cytometry core at Boston University Chobanian and Avedisian School of  
645 Medicine, and all the NEIDL animal core staff for their outstanding support. We also thank all the  
646 Douam, Balazs, Connor and Crossland lab members, NEIDL members, and members of the  
647 department of Virology, Immunology, and Microbiology and Pathology at Boston University for

648 their constant support and advice. D.K. is supported by a T32 training grant in immunology  
649 (T32AI007309).

650

## 651 **MATERIALS AND METHODS**

652 Detailed descriptions of the materials and methods used for this study are in the Supplemental  
653 Materials.

654

655 **Study design.** Three independent cohorts of BLT-L mice co-engrafted with human fLX, liver,  
656 thymus and hematopoietic stem cells from three distinct donors were generated for this study.  
657 Animals were challenged with SARS-CoV-2 ( $10^6$  PFU) through direct fLX inoculation, and  
658 euthanized on day 2, 6 or 12 post-infection for blood and fLX collection. Naïve mice were used  
659 as negative controls. fLX were then processed for viral titer quantification, H&E staining and  
660 mIHC, scRNAseq and viral genome sequencing. Blood was processed for flow cytometry (for  
661 depletion experiments only) and serum cytokine analysis. For CD3+, CD4+ and CD8+ cell  
662 depletion, mice were treated with depleting antibodies prior and during infection through  
663 intraperitoneal injection.

664

665 **Institutional approvals.** All experiments in this study, including those conducted in BSL-3, were  
666 approved by an institutional biosafety committee. Animal experiments described in this study were  
667 performed in accordance with protocols that were reviewed and approved by the Institutional  
668 Animal Care and Use and Committee of the Ragon Institution and Boston University. All mice  
669 were maintained in facilities accredited by the Association for the Assessment and Accreditation  
670 of Laboratory Animal Care (AAALAC). All replication-competent SARS-CoV-2 experiments were  
671 performed in a biosafety level 3 laboratory (BSL-3) at the Boston University National Emerging  
672 Infectious Diseases Laboratories (NEIDL).

673

674 **Mouse strains and sex as biological variable.** Female NOD.Cg.-*Prkdc*<sup>Scid</sup>*Il2rg*<sup>tm1Wjl</sup>/SzJ (NSG)  
675 mice were obtained from the Jackson Laboratory, catalog number 005557. NSG mice were  
676 maintained by the Ragon Institute Human Immune System Mouse core prior to engraftment and  
677 shipment to the NEIDL, Boston University. In our study, only female mice were engrafted with  
678 human fetal tissues because of their ability to support higher levels of engraftment than males.  
679 As we investigated human tissue responses to infection and only leveraged mice as  
680 xenorecipients, the sex of the animals does represent a critical variable for our study.

681

682 **Human fetal tissues.** De-identified human fetal tissues were procured from Advanced Bioscience  
683 Resources (Alameda, CA, USA).

684

685 **Generation of BLT-L mice.** BLT mice were generated via irradiation of female NOD.Cg.-  
686 *Prkdc*<sup>Scid</sup>*Il2rg*<sup>tm1Wjl</sup>/SzJ mice (NSG mice; Jackson Laboratory #005557) prior to implantation of  
687 human fetal thymic and fetal liver tissue (Advanced Bioscience Resources) under the murine  
688 kidney capsula. Two pieces of homologous human fetal lung tissue were implanted into  
689 subcutaneous dorsal pockets of mice. Post-implantation, mice intravenously received  $1 \times 10^5$   
690 homologous CD34+ cells. Human immune reconstitution was determined by flow cytometry at  
691 weeks post-implantation. Three distinct human donors were used for this study.

692

693 **Mouse inoculation with SARS-CoV-2.** BLT-L mice were anesthetized with 1–3% isoflurane prior  
694 to inoculation via subcutaneous, intra-fetal lung xenograft (intra-fLX) injection with  $10^6$  plaque  
695 forming unites (PFU) of SARS-CoV-2 WA-1 isolate in 50  $\mu$ L of sterile 1X PBS. Mice were  
696 euthanized at 2-, 6-, and 12-days post inoculation.

697

698 ***In vivo antibody depletion.*** BLT-L mice were administered 200 mg of anti-CD3e (OKT3)  
699 (BioxCell; cat. # BE0001-2), anti-CD4 (OKT4) (BioxCell; cat. # BE0003-2), anti-CD8 (OKT8)  
700 (BioxCell; cat. # BE0004-2), or isotype IgG2a (Thermofisher; cat # 02-6200) antibody 3-, 2-, and  
701 1-day prior to inoculation and 4- and 8-days post inoculation with  $1 \times 10^6$  PFU SARS-CoV-2 WA-  
702 1.

703  
704 ***Quantification and statistical Analysis.*** For histopathological score and viral load/titer  
705 comparisons a Kruskla-Wallis, non-parametric one-way ANOVA with Benjamini, Krieger, and  
706 Yekutieli correction for multiple comparisons was applied given the non-continuous nature of the  
707 data. For cytokine data, an Ordinary one-way ANOVA with uncorrected Fishers LSD was used  
708 as the data was collected from different time points, treatment conditions, and cohorts. A Kruskla-  
709 Wallis, non-parametric one-way ANOVA with an uncorrected Dunn's test was applied for CD163+  
710 Area quantification (AQ) due to the independent comparisons between the samples. All statistical  
711 tests and graphical depictions of results were performed using GraphPad Prism version 9.0.1  
712 software (GraphPad Software, La Jolla, CA). For all tests,  $p \leq 0.05$  was considered statistically  
713 significant. Statistical significance on figures and supplemental figures is labeled with p-values  
714 and non-significant values are labeled with n.s. or left unlabeled.

715  
716 ***Data availability.*** The accession number for the raw data of the bulk and single-cell RNA-Seq is  
717 GSE255200.

718  
719 **REFERENCES**


- 720 1. R. G. H. Lindeboom *et al.*, Human SARS-CoV-2 challenge uncovers local and systemic  
721 response dynamics. *Nature*, (2024).  
722 2. Y. Di *et al.*, SARS-CoV-2 Variant-Specific Infectivity and Immune Profiles Are Detectable  
723 in a Humanized Lung Mouse Model. *Viruses* **14**, (2022).  
724 3. D. J. Kenney *et al.*, Humanized mice reveal a macrophage-enriched gene signature  
725 defining human lung tissue protection during SARS-CoV-2 infection. *Cell Rep* **39**, 110714  
726 (2022).

- 727 4. R. Sun *et al.*, Humanized mice for investigating SARS-CoV-2 lung infection and  
728 associated human immune responses. *Eur J Immunol* **52**, 1640-1647 (2022).
- 729 5. A. Wahl *et al.*, Precision mouse models with expanded tropism for human pathogens. *Nat*  
730 *Biotechnol* **37**, 1163-1173 (2019).
- 731 6. A. K. O'Connell, F. Douam, Humanized Mice for Live-Attenuated Vaccine Research: From  
732 Unmet Potential to New Promises. *Vaccines (Basel)* **8**, (2020).
- 733 7. PMDA, Xevudy for Intravenous Infusion 500 mg\_GlaxoSmithKline K.K.\_Report on Special  
734 Approval for Emergency; <https://www.pmda.go.jp/files/000245006.pdf>. (2021).
- 735 8. A. Fagre *et al.*, SARS-CoV-2 infection, neuropathogenesis and transmission among deer  
736 mice: Implications for spillback to New World rodents. *PLoS Pathog* **17**, e1009585 (2021).
- 737 9. N. Arshad *et al.*, SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct  
738 mechanisms to down-regulate MHC-I surface expression. *Proc Natl Acad Sci U S A* **120**,  
739 e2208525120 (2023).
- 740 10. J. S. Yoo *et al.*, SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting  
741 the STAT1-IRF1-NLRC5 axis. *Nat Commun* **12**, 6602 (2021).
- 742 11. T. M. Delorey *et al.*, COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular  
743 targets. *Nature*, (2021).
- 744 12. A. F. Rendeiro *et al.*, The spatial landscape of lung pathology during COVID-19  
745 progression. *Nature* **593**, 564-569 (2021).
- 746 13. E. Wauters *et al.*, Discriminating mild from critical COVID-19 by innate and adaptive  
747 immune single-cell profiling of bronchoalveolar lavages. *Cell Res* **31**, 272-290 (2021).
- 748 14. A. Wu, H. Song, Regulation of alveolar type 2 stem/progenitor cells in lung injury and  
749 regeneration. *Acta Biochim Biophys Sin (Shanghai)* **52**, 716-722 (2020).
- 750 15. J. Huang *et al.*, SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung  
751 Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. *Cell stem*  
752 *cell* **27**, 962+ (2020).
- 753 16. J. C. Melms *et al.*, A molecular single-cell lung atlas of lethal COVID-19. *Nature* **595**, 114-  
754 119 (2021).
- 755 17. M. Liao *et al.*, Single-cell landscape of bronchoalveolar immune cells in patients with  
756 COVID-19. *Nat Med* **26**, 842-844 (2020).
- 757 18. C. Harly, M. Cam, J. Kaye, A. Bhandoola, Development and differentiation of early innate  
758 lymphoid progenitors. *J Exp Med* **215**, 249-262 (2018).
- 759 19. G. Pizzolato *et al.*, Single-cell RNA sequencing unveils the shared and the distinct  
760 cytotoxic hallmarks of human TCRVdelta1 and TCRVdelta2 gammadelta T lymphocytes.  
761 *Proc Natl Acad Sci U S A* **116**, 11906-11915 (2019).
- 762 20. A. Zhen *et al.*, CD4 ligation on human blood monocytes triggers macrophage  
763 differentiation and enhances HIV infection. *J Virol* **88**, 9934-9946 (2014).
- 764 21. L. Jardine *et al.*, Rapid detection of dendritic cell and monocyte disorders using CD4 as a  
765 lineage marker of the human peripheral blood antigen-presenting cell compartment. *Front*  
766 *Immunol* **4**, 495 (2013).
- 767 22. L. Fu, Z. Liu, Y. Liu, Fibrinogen-like protein 2 in inflammatory diseases: A future  
768 therapeutic target. *Int Immunopharmacol* **116**, 109799 (2023).
- 769 23. Y. Takakura *et al.*, Mitochondrial protein C15ORF48 is a stress-independent inducer of  
770 autophagy that regulates oxidative stress and autoimmunity. *Nat Commun* **15**, 953 (2024).
- 771 24. S. A. Clayton *et al.*, Inflammation causes remodeling of mitochondrial cytochrome c  
772 oxidase mediated by the bifunctional gene C15orf48. *Sci Adv* **7**, eabl5182 (2021).
- 773 25. J. Schyns *et al.*, Non-classical tissue monocytes and two functionally distinct populations  
774 of interstitial macrophages populate the mouse lung. *Nat Commun* **10**, 3964 (2019).
- 775 26. D. Wendisch *et al.*, SARS-CoV-2 infection triggers profibrotic macrophage responses and  
776 lung fibrosis. *Cell* **184**, 6243-6261 e6227 (2021).



- 777 27. E. Evren *et al.*, Distinct developmental pathways from blood monocytes generate human  
778 lung macrophage diversity. *Immunity* **54**, 259-275 e257 (2021).
- 779 28. T. Hussell, T. J. Bell, Alveolar macrophages: plasticity in a tissue-specific context. *Nat Rev*  
780 *Immunol* **14**, 81-93 (2014).
- 781 29. J. K. Damas *et al.*, Homeostatic chemokines CCL19 and CCL21 promote inflammation in  
782 human immunodeficiency virus-infected patients with ongoing viral replication. *Clin Exp*  
783 *Immunol* **157**, 400-407 (2009).
- 784 30. E. I. Zuniga, M. Macal, G. M. Lewis, J. A. Harker, Innate and Adaptive Immune Regulation  
785 During Chronic Viral Infections. *Annu Rev Virol* **2**, 573-597 (2015).
- 786 31. A. Wahl *et al.*, SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.  
787 *Nature* **591**, 451-457 (2021).
- 788 32. M. P. Rodero *et al.*, Immune surveillance of the lung by migrating tissue monocytes. *Elife*  
789 **4**, e07847 (2015).
- 790 33. P. R. Dunbar *et al.*, Pulmonary monocytes interact with effector T cells in the lung tissue  
791 to drive T(RM) differentiation following viral infection. *Mucosal Immunol* **13**, 161-171  
792 (2020).
- 793 34. J. Zheng *et al.*, Severe Acute Respiratory Syndrome Coronavirus 2-Induced Immune  
794 Activation and Death of Monocyte-Derived Human Macrophages and Dendritic Cells. *J*  
795 *Infect Dis* **223**, 785-795 (2021).
- 796 35. A. Boumaza *et al.*, Monocytes and Macrophages, Targets of Severe Acute Respiratory  
797 Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis. *J*  
798 *Infect Dis* **224**, 395-406 (2021).
- 799 36. D. Yang *et al.*, Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-  
800 Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1  
801 Phosphorylation. *J Infect Dis* **222**, 734-745 (2020).
- 802 37. C. Junqueira *et al.*, FcγR-mediated SARS-CoV-2 infection of monocytes activates  
803 inflammation. *Nature* **606**, 576-584 (2022).
- 804 38. D. Munnur *et al.*, Altered ISGylation drives aberrant macrophage-dependent immune  
805 responses during SARS-CoV-2 infection. *Nat Immunol* **22**, 1416-1427 (2021).
- 806 39. E. Sefik *et al.*, Inflammasome activation in infected macrophages drives COVID-19  
807 pathology. *Nature* **606**, 585-593 (2022).
- 808 40. Y. Qian *et al.*, Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein  
809 Is Blocked by Simvastatin. *J Virol* **95**, e0139621 (2021).
- 810 41. M. Molgora, M. Colonna, Innate-like T cells: A promising asset in anti-cancer immunity.  
811 *Cancer Cell* **40**, 714-716 (2022).
- 812 42. M. Lebedev, B. Faburay, J. A. Richt, A. Young, Myeloid-like gammadelta T cell subset in  
813 the immune response to an experimental Rift Valley fever vaccine in sheep. *Vet Immunol*  
814 *Immunopathol* **233**, 110184 (2021).
- 815 43. M. Muto, M. Baghdadi, R. Maekawa, H. Wada, K. Seino, Myeloid molecular characteristics  
816 of human gammadelta T cells support their acquisition of tumor antigen-presenting  
817 capacity. *Cancer Immunol Immunother* **64**, 941-949 (2015).

818



819

820 **Figure 1. BLT-L mice effectively resolve SARS-CoV-2 infection and repair lung tissue.** Fetal

821 lung xenografts (fLX) of BLT-L mice were infected with  $1 \times 10^6$  PFU of SARS-CoV-2 WA-1 isolate

822 via subcutaneous intra-graft injection. **(A)** BLT-L mice were monitored for weight change over the

823 course of 12-days post infection (dpi). **(B)** Immunohistochemistry for SARS-CoV-2 S protein **(a-**

824 **d)** and hematoxylin and eosin staining **(e-f)** were performed on naïve fLX **(a,e)** and fLX at 2 dpi

825 **(b,f)**, 6 dpi **(c,g)**, and 12 dpi **(d,h)**. Scale bar = 100  $\mu$ M **(C)** Viral titer (log(PFU/mg)) in fLX at 2, 6,

826 and 12 dpi as determined by plaque assay. **(D)** Histopathological scoring of naïve fLX and fLX at


827 2, 6, and 12 dpi. Data are representative of two or three independent experiments.  $n = 6 - 10$  per

828 timepoint. Error bars represent mean  $\pm$  standard error of the mean. *One-way ANOVA analysis*

829 *was performed. p-values are indicated. n.s. = non-significant.*

830





832 **Figure 2. Systemic depletion of CD4<sup>+</sup> cells results in persistent infection of fLX. (A)** BLT-L  
833 mice were administered 200  $\mu$ g of anti-CD3e (OKT3), anti-CD4 (OKT4), anti-CD8 (OKT8) or  
834 IgG2a isotype. **(B)** Viral titer (log(PFU/mg)) in fLX extracted from BLT-L mice treated with isotype,  
835 OKT3, OKT4, or OKT8 antibody at 12 dpi. **(C)** Immunohistochemistry for SARS-CoV-2 N protein  
836 on fLX of depleted or non-depleted BLT-L mice at 12 dpi. **(D)** Multiplex immunohistochemistry on  
837 fLX of depleted or non-depleted BLT-L mice at 12 dpi. Dapi = gray, CD3 = teal, CD4 = red. Scale  
838 bar = 50  $\mu$ m. **(E)** MHC-I staining of fLX tissue sections (anti-MHC class I (EMR8-5) CST 88274)  
839 extracted from naïve mice, OKT4-treated mice (12 dpi), or from infected fLX at 2 and 12 dpi. Scale  
840 bar = 100  $\mu$ M

841

842

843

844

845

846

847

848

849

850

851


852

853

854

855

856



857

858

859

860 **Figure 3. Cellular remodeling and viral dynamics in fLX upon SARS-CoV-2 infection**

861 Single cell RNA sequencing analysis was performed on single cell suspensions of naïve fLX and  
862 fLX at 2 and 12 dpi. Naïve n=3 fLX (9,605 cells), 2 dpi n=2 fLX (4,405 cells), and 12 dpi n = 2 fLX  
863 (5,857 cells). **(A)** UMAP plot clustering of the human cell compartment of naïve fLX and fLX at 2  
864 and 12 dpi. **(B)** Temporal annotation of the human clusters on the UMAP plot: naïve (black), 2 dpi  
865 (red), 12 dpi (blue). Sub-clusters unique to 2 dpi are annotated by A (T cell compartment), B  
866 (myeloid compartment) and C (mesenchymal compartment). **(C)** Frequency of each cell  
867 compartment determined by single cell RNA-sequencing. **(D)** Dot plots displaying the expression  
868 of SARS-CoV-2 viral RNA transcripts identified in scRNA-seq. **(E)** UMAP plot showing the  
869 distribution of SARS-CoV-2 viral RNA transcripts across all human cell clusters and time points.  
870 **(F)** UMAP plot sub-clustering of the human AT2 compartment in fLX across all time points. **(G)**  
871 Temporal annotation of the human epithelial sub-clusters on the UMAP plot: naïve (black), 2 dpi  
872 (red), 12 dpi (blue). The inset graph indicates the change in frequency of each compartment (AT2;  
873 black, Basal; pink, Secretory; teal, and AT1; purple) within the epithelial compartment. Red line  
874 indicates the change in the AT2 compartment over time. **(H)** Heatmap displaying the relative  
875 expression (from -1 to 1) of the top differentially regulated genes over the course of infection within  
876 the AT2 compartment.

877

878

879


880

881

882

883





884

885

886 **Figure 4. CD163+ extravascular inflammatory monocytes arise during acute viral infection**  
887 **and are predominant antiviral mediators. (A)** UMAP plot showing sub-clustering of the human  
888 myeloid compartment of fLX across all time points. **(B)** Temporal annotation of the myeloid sub-  
889 clusters on the UMAP plot: naïve (black), 2 dpi (red), 12 dpi (blue). ExiMO sub-cluster is indicated  
890 with a blue circle. **(C)** UMAP plot (all time points) showing the distribution of SARS-CoV-2 viral  
891 RNA transcripts in the myeloid compartment. **(D-F)** UMAP plot showing the expression of CD163  
892 **(D)**, CD4 **(E)**, and MRC1 **(F)** across myeloid sub-sets. **(G)** Frequency of each myeloid sub-cluster  
893 by timepoint. **(H)** Relative expression of highly upregulated ISGs and inflammatory markers in  
894 each of the myeloid sub-clusters. **(I)** Violin plots showing expression level of differentially  
895 expressed genes between SARS-CoV-2 positive and negative ExiMO (sub-cluster 3). **(J)**  
896 Schematic representation of proposed temporal myeloid dynamics during infection. Black arrows  
897 represent differentiation dynamics during infection. **(K)** Multiplex fluorescent  
898 immunohistochemistry of naïve fLX and fLX at 2 and 12 dpi. CD163: teal, CD4: yellow, CD3:  
899 orange, PPAR $\gamma$ : green, Dapi: gray. Two representative images. Scale bar = 100  $\mu$ M.

900

901

902

903

904


905

906

907


908

909



910

911 **Figure 5. CD4+ cell depletion reduces CD163+ recruitment in fLX, promotes immune**  
 912 **tolerance and results in signatures of chronic infection. (A-B)** Multiplex fluorescent  
 913 immunohistochemistry (A) and CD163+ area quantification (AQ) (B) of fLX that resolved infection  
 914 (12 dpi, isotype treated), or eliciting acute (2 dpi) or persistent infection (12 dpi, OKT4 treated).  
 915 CD163: teal, CD4: yellow, CD3: orange, PPAR $\gamma$ : green, Dapi: gray. Scale bar = 50  $\mu$ M. **(C-E)**  
 916 Cytokine quantification (C: CCL2/3, D: CXCL10, E: CCL19) in the serum of naïve, infected (2 dpi  
 917 and 12 dpi isotype-treated or not) and OKT4-treated BLT-L mice (12 dpi). **(F)** Histopathological  
 918 scoring of fLX extracted from isotype and OKT4-depleted BLT-L mice (12 dpi). Error bars indicate  
 919 mean  $\pm$  Standard error of the mean. One-way ANOVA, *t*-test. *p*-values are indicated on graphs.




920

921 **Figure 6. Macrophage-like T-cell emerges upon acute infection and are enriched in viral**  
 922 **RNA. (A)** UMAP plot showing the sub-clustering of the human T-cell compartment of fLX across  
 923 all time points. **(B)** Temporal annotation of the human T-cell sub-clusters on the UMAP plot: naïve  
 924 (black), 2 dpi (red), 12 dpi (blue). **(C)** UMAP plot (all time points) showing the distribution of SARS-  
 925 CoV-2 viral RNA transcripts in the T-cell compartment. **(D)** Go-term analysis showing the most  
 926 highly upregulated signaling pathways in the macrophage-like T-cell sub-cluster (sub-cluster 6).  
 927 **(E)** Relative expression of T-cells, macrophage, mesenchymal and antiviral markers within each  
 928 of the T-cell sub-clusters (From 0 to 7; as labeled in panel A.).

929

930





931

932 **Figure 7. The inflammatory fate of ExiMO may define the clinical course of SARS-CoV-2**

933 **infection.** During mild COVID-19 disease (left window), robust ExiMO antiviral responses and

934 phagocytosis drive infection resolution in the absence of differentiation into CD206- inflammatory

935 interstitial macrophages (1). Mild tissue damage caused by virally-induced cytopathic effects and

936 moderate inflammation drive the recruitment of CD206+ interstitial macrophages, which promote

937 tissue repair (2). During severe COVID-19 disease (right window), ExiMO differentiate into

938 CD206- inflammatory interstitial macrophages. Antiviral responses and inflammation are

939 exacerbated, triggering an inflammatory positive-feedback loop resolving infection at the expense

940 of severe tissue damage (1). Such damages promote the extensive recruitment of CD206+

941 interstitial macrophages with pro-fibrotic functions, favoring the development of lung fibrosis and

942 increasing the incidence of ARDS (2).

943

944

945

946

